AVIDITY BIOSCIENCES ($NASDAQ:RNA) released their second quarter of FY2023 earning results on August 8 2023, demonstrating total revenue of USD 2.3 million, a 6.4% growth from the same period in FY2022. However, net income for the quarter was USD -47.0 million, a decrease of USD -1.3 million from the previous year.
Analysis – Avidity Biosciences Intrinsic Value Calculator
GoodWhale’s financial analysis of AVIDITY BIOSCIENCES has revealed an undervaluation of its stock. According to GoodWhale’s proprietary Valuation Line, the fair value of AVIDITY BIOSCIENCES is estimated to be around $15.2. This indicates that the current trading price of $8.9 per share is undervalued by 41.5%. Investors looking for a bargain should strongly consider taking advantage of this stock’s great value. With its current undervaluation, now may be the best time to invest in AVIDITY BIOSCIENCES. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Avidity Biosciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Avidity Biosciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Avidity Biosciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Avidity Biosciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The Company is engaged in the development and commercialization of therapeutics to treat rare and intractable diseases. It has developed AVID200, an antibody that neutralizes all four serotypes of dengue virus. The Company’s competitors include ProQR Therapeutics NV, Hansa Biopharma AB and Merus NV.
– ProQR Therapeutics NV ($NASDAQ:PRQR)
ProQR Therapeutics NV is a company that focuses on the development of RNA-based therapeutics for the treatment of serious genetic disorders. The company has a market cap of 96.44M as of 2022 and a return on equity of -57.53%. ProQR Therapeutics NV is a company that focuses on the development of RNA-based therapeutics for the treatment of serious genetic disorders.
Hansa Biopharma is a Swedish biopharmaceutical company that develops immunotherapies for the treatment of cancer and other diseases. The company has a market cap of 214.59M as of 2022 and a return on equity of -91.55%. Hansa Biopharma’s products are based on its proprietary platform technology, which is designed to target specific immune cells and modulate their activity. The company’s lead product candidate, imlifidase, is in clinical development for the treatment of solid tumors and hematologic malignancies.
Merus NV is a Dutch biopharmaceutical company. The company has a market cap of 759.83M as of 2022 and a Return on Equity of -25.83%. The company is focused on the development of antibody therapeutics for the treatment of cancer. The company’s lead product is MCLA-128, an antibody that targets the ErbB3 receptor, which is overexpressed in a number of solid tumors.
Avidity Biosciences reported their second quarter FY2023 earnings results on August 8 2023, with total revenue of USD 2.3 million, a 6.4% increase year-over-year. Net income for the quarter was USD -47.0 million, a decrease of USD -1.3 million from the prior year. Investors should take a closer look at the results in order to evaluate the company’s performance and outlook. Factors such as cash flow, revenue growth, expenses, and management’s vision can all be used to evaluate the company’s long-term prospects.
Additionally, investors should carefully analyze the competitive landscape and the current macroeconomic environment to assess whether the company will be able to sustain its current level of performance.